Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Among patients treated with adjuvant VEGFR TKIs for RCC, drug-host interactions mediate changes in circulating cytokines. 31471309 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE We confirmed that positive MYOF expression and negative VEGFR2 expression were positively correlated in this CCRCC population. 31477752 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. 31075726 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE It drives tumorigenesis by activating downstream hypoxia responsive genes and proangiogenic factors like VEGFR, and is responsible for the activity of tyrosine kinase inhibitors in RCC. 31184937 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC); in combination with antiangiogenic VEGF/VEGFR2 inhibitors (e.g., bevacizumab and sunitinib) for metastatic RCC; and in combination with chemotherapeutics as neoadjuvant (preoperative) therapies for resectable TNBC. 30498230 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE The inverse association of angiogenesis gene signature with ccRCC histologic grade highlight opportunities for adjuvant combination VEGFR2 tyrosine kinase inhibitor and immune-checkpoint inhibition. 31767020 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Together, these data suggest that combination of S1P1 and VEGFR-targeted therapy may be a useful therapeutic strategy for the treatment of renal cell carcinoma and other tumor types. 30787172 2019
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE Renal cell carcinoma (RCC) is highly dependent on angiogenesis, due to the overactivation of the VHL/HIF/VEGF/VEGFRs axis; this justifies the marked sensitivity of this neoplasm to antiangiogenic agents which, however, ultimately fail to control tumor growth. 30447930 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). 30380460 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Axitinib is an approved drug that targets the vascular endothelial growth factor receptor 2 (VEGFR2) and is licensed for second-line therapy of renal cell carcinoma. 30199151 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Over the past decade, therapies targeting the VEGF/VEGFR and mTOR pathways have served as the standard of care for the clinical management of renal cell carcinoma (RCC) patients. 29930727 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Structure-Based Virtual Screening for the Identification of High Affinity Compounds as Potent VEGFR2 Inhibitors for the Treatment of Renal Cell Carcinoma. 30499413 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE Finally, we used a coculture model of human umbilical vein endothelial cells with RCC cell lines to find out that HMGB1 also increased the expression of VEGF and VEGFR2 in human umbilical vein endothelial cells. 30122942 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Tivozanib received its first global approval in EU, Iceland, and Norway on 28 August 2017 for the first-line treatment of adult patients with advanced RCC and for adult patients who are VEGFR and mTOR inhibitor-naive following disease progression after one prior treatment with cytokines. 29851529 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE 658 patients with advanced RCC who had received at least one prior VEGFR tyrosine kinase inhibitor were randomised 1:1 to cabozantinib (60 mg daily) or everolimus (10 mg daily). 29576624 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability. 30084668 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC. 29460635 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy. 29667066 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. 29784193 2018
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE It has recently been approved by the European Medicines Agency (EMA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive, following disease progression after one prior treatment with cytokine therapy for advanced RCC. 29451277 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. 28756136 2017
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE This study describes the relationship among proliferation, survival, and apoptosis with the expression of key molecules related to tumoral hypoxia (hypoxia-inducible factor (HIF)-1α, erythropoietin (EPO), vascular endothelial growth factor (VEGF)), their receptors (EPO-R, VEGFR-2), and stearoyl desaturase-1 (SCD-1) in early stages of ccRCC. 27468719 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE There are no effective therapies for advanced renal cell carcinoma (RCC), except for VEGFR inhibitors with only ~50% response rate. 27035563 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. 27248821 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE Our findings demonstrate for the first time that CHIP may be involved in RCC angiogenesis through regulating VEGF secretion and expression of VEGFR2. 26021863 2015